Lomefloxacin Aspartate Injection

Lomeza is a broad-spectrum quinolone antibacterial drug that has bactericidal effects on Gram-negative bacteria, Gram-positive bacteria and some anaerobic bacteria. It has good antibacterial effects on methicillin-resistant Staphylococcus aureus, ampicillin-resistant influenza bacilli, pipemidic acid-resistant Escherichia coli and bacteria resistant to other drugs. Its antibacterial mechanism is to inhibit the activity of bacterial DNA helicase, thereby inhibiting bacterial DNA transcription and replication, and has bactericidal effects on a variety of Gram-positive and Gram-negative bacteria.

The main ingredient of this product is lomefloxacin aspartate, and its chemical name is: 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid aspartate

Suitable for the following infections caused by sensitive bacteria: 1. Respiratory tract infections: acute exacerbation of chronic bronchitis, bronchiectasis with infection, acute bronchitis, pneumonia, etc. 2. Urinary and reproductive system infections: acute cystitis, acute pyelonephritis, complicated urinary tract infection, acute exacerbation of chronic urinary tract infection, acute and chronic prostatitis, simple gonorrhea, etc. 3. Infections of the abdominal cavity, bile duct, intestines, typhoid fever, etc. 4. Skin and soft tissue infections. 5. Other infections, such as sinusitis, otitis media, blepharitis, etc.

Intravenous drip: Adults 0.2 g each time, diluted in 5% glucose injection or 250 ml of normal saline, drip time for no less than 60 minutes per 100 ml, twice a day, or as directed by a doctor.

1. Common adverse reactions of lomefloxacin are mainly: headache, nausea, vomiting, photosensitivity, dizziness, diarrhea and abdominal pain, etc. 2. The following adverse reactions have been observed in lomefloxacin: Autonomic: increased sweating, thirst, flushing, etc.; Physical: fatigue, back pain, depression, weakness, etc.; Cardiovascular: palpitations, hyperactivity, hypertension, hypotension, myocardial infarction, angina pectoris, etc.; Central nervous system and peripheral nervous system: tremor, dizziness, paresthesia, convulsions, epileptic seizures, etc.; Gastrointestinal: indigestion benign, vomiting, constipation, gastrointestinal bleeding, dysphagia, etc.; hematology: purpura, lymphadenopathy, thrombocytosis, anemia, etc.; liver, kidney: increased serum amino acid transferase, BUN value; metabolism: thirst, hyperglycemia; musculoskeletal: arthralgia, myalgia, leg cramps; ophthalmology: abnormal vision, conjunctivitis, photophobia, etc.; psychiatry: insomnia, neurosis, hallucinations, depression; reproductive system: female: candidiasis, vaginitis, menstrual abnormalities, etc.; male: epididymitis, orchitis. Respiratory system: respiratory tract infection, rhinitis, pharyngitis, dyspnea, etc. Skin/allergy: pruritus, urticaria, skin exfoliation, etc.; exudative multiforme erythema and angioneurotic edema may occasionally occur; special senses: abnormal taste. Urinary tract: hematuria, crystalluria, frequent urination, dysuria, anuria, etc. Local: phlebitis

Patients who are allergic to this product or other quinolones are contraindicated.

1Theophylline: In clinical studies of long-term use of theophylline, lomefloxacin had no significant effect on theophylline concentration. 2Caffeine: 200 mg of caffeine was given to healthy volunteers who had reached steady-state lomefloxacin blood concentrations, which did not cause statistically significant differences, and did not cause changes in the pharmacokinetic parameters of caffeine and its main metabolites. 3Cimetidine: Cimetidine can interfere with the elimination of other quinolone drugs, resulting in an increase in half-life and AUC. The interaction between cimetidine and lomefloxacin has not been studied. 4Cyclosporin: Cyclosporin and other quinolones can increase the serum concentration of cyclosporin. The interaction between cyclosporin and lomefloxacin has not been studied. 5Omeprazole: Multiple doses of omeprazole followed by a single dose of lomefloxacin did not cause significant changes in the pharmacokinetic parameters of lomefloxacin (AUC, Cmax, tmax), and the pharmacokinetic changes of omeprazole have not been studied. 6 Phenytoin sodium: When phenytoin sodium extended-release capsules were co-administered with lomefloxacin for 5 days, there was no significant change in the pharmacokinetic parameters of phenytoin sodium, AUC, Cmax, Cmin or tmax. Lomefloxacin may not have a significant effect on the metabolism of phenytoin. 7 Terfenadine: In a steady-state study of 28 healthy men, the co-administration of terfenadine and lomefloxacin did not significantly change the heart rhythm or QT interval, the pharmacokinetics of terfenadine or lomefloxacin. 8 Warfarin: Quinolones can enhance the effects of the coagulation drug warfarin or its derivatives. When these drugs are used in combination, the prothrombin time or other coagulation tests should be closely monitored. However, when warfarin and lomefloxacin were co-administered under steady-state conditions, there was no significant change in the clotting time ratio or the pharmacokinetics of warfarin enantiomers. 9 Antacids and sucralfate: Antacids and sucralfate containing magnesium or aluminum, as well as preparations containing divalent and trivalent ions such as dideoxycreatinine, can form complexes with lomefloxacin and interfere with the bioavailability of lomefloxacin. 10 Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity.

Keep in a dark, airtight container in a cool place.

2ml:0.1g

Hubei Qianjiang Pharmaceutical Co., Ltd.

• Founded in:

  2009-09-18

• Address:

  No. 1, Zhanghua South Road, Qianjiang City

• Tax NO.:

  91429005695102248D

• Registered Funds:

  300 million yuan

• Website:

  Log in to view

• Email:

  Log in to view